SPONSOR
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 1, Phase 2
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Systemic Sclerosis, Multiple Myeloma.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
How many clinical trials has Juno Therapeutics, Inc., a Bristol-Myers Squibb Company sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, of which 3 are actively recruiting participants. These trials cover conditions including Systemic Sclerosis, Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Juno Therapeutics, Inc., a Bristol-Myers Squibb Company research focus on?
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company clinical trials span Systemic Sclerosis, Multiple Myeloma. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Juno Therapeutics, Inc., a Bristol-Myers Squibb Company clinical trial?
To participate in a Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials with current recruitment status updated daily.
Clinical Trials by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT07335562 Phase 3
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
NCT06121843 Phase 1
Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
NCT06297226 Phase 2
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology